Compounds > quinoxalines
Page last updated: 2024-08-17

quinoxalines and dihydroxyphenylalanine

quinoxalines has been researched along with dihydroxyphenylalanine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G1
Aizenman, E; Loring, R; Rosenberg, PA; Xie, Y; Zaleskas, V1
Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF1
Aizenman, E; Loring, RH; Rosenberg, PA; White, WF1
Bennett, JP; Richard, MG1
García-Sevilla, JA; Garro, MA; Giralt, MT; Menargues, A; Miralles, A; Obach, R; Olmos, G; Pineda, J; Ugedo, L1

Other Studies

6 other study(ies) available for quinoxalines and dihydroxyphenylalanine

ArticleYear
Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 263, Issue:3

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebellum; Dihydroxyphenylalanine; G(M1) Ganglioside; Mesencephalon; MPTP Poisoning; Oxidation-Reduction; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley

1992
2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin.
    Proceedings of the National Academy of Sciences of the United States of America, 1991, Jun-01, Volume: 88, Issue:11

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebral Cortex; Chickens; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Eye; In Vitro Techniques; Neurons; Neurotoxins; Ocular Physiological Phenomena; Quinoxalines; Rats

1991
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
    Experimental neurology, 1990, Volume: 108, Issue:3

    Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina

1990
A 3,4-dihydroxyphenylalanine oxidation product is a non-N-methyl-D-aspartate glutamatergic agonist in rat cortical neurons.
    Neuroscience letters, 1990, Aug-14, Volume: 116, Issue:1-2

    Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebral Cortex; Dihydroxyphenylalanine; Evoked Potentials; N-Methylaspartate; Neurons; Quinoxalines; Rats

1990
NMDA receptor blockade increases in vivo striatal dopamine synthesis and release in rats and mice with incomplete, dopamine-depleting, nigrostriatal lesions.
    Journal of neurochemistry, 1995, Volume: 64, Issue:5

    Topics: Animals; Arginine; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Excitatory Amino Acids; Male; Mice; Microdialysis; Nitroarginine; Oxidopamine; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Valine

1995
Acute and chronic effects of reserpine on biochemical and functional parameters of central and peripheral alpha 2-adrenoceptors.
    European journal of pharmacology, 1993, Aug-03, Volume: 239, Issue:1-3

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Binding Sites; Brain; Brimonidine Tartrate; Clonidine; Dihydroxyphenylalanine; Dioxanes; Idazoxan; Injections, Subcutaneous; Male; Mydriasis; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Reserpine; Tyrosine 3-Monooxygenase; Vas Deferens

1993